Objectives: Influenza viruses can result in a variety of uncommon but serious neurological complications. This study aimed to (a) assess the prevalence of INAC in children with confirmed influenza A or B virus infection. (b) Describe this population's clinical features, neuroimaging, laboratory, treatment, and outcome.
Methods: This retrospective cohort research screened all individuals under 18 years of age with influenza virus confirmed by polymerase chain reaction (PCR) for IANC from January 2012 to January 2023. Only patients eligible for the diagnosis of IANC were included in the analysis. Demographic, clinical, laboratory, and neuroimaging information was extracted from medical records. The statistical analysis was conducted utilizing SPSS version 29.
Results: Six hundred eighty patients with confirmed influenza A/B infection were evaluated for IANC. Forty-eight patients (7.1%) received treatment for IANC at a median age of 4.0 years. Approximately 7.2% of males and 6.9% of females exhibited IANC. The majority of patients (85.4%, 41/48) exhibited IANC with central nervous system involvement, (12.5%, 6/48) demonstrated peripheral nervous system involvement, and only one instance (2%) involved both systems. In children with IANC, febrile seizures, influenza-related encephalopathy, and acute necrotizing encephalopathy were observed in 39.5%, 23.7%, and 13.2% of cases, respectively. Only immunological comorbidities (p = 0.005) and encephalopathy (p = 0.006) significantly contributed to mortality, with 5 out of 48 children (10.4%) succumbing.
Conclusion: IANC, however rare, poses a significant hazard to life and exhibits a high mortality rate. IANC is more prevalent in children under 5 years, underscoring the significance of influenza immunization in this population.

